(Q37625449)

21 August 2017

1 reference

title

Management of endometrial cancer in Asia: consensus statement from the Asian Oncology Summit 2009. (English)

1 reference

21 August 2017

1 reference

Siriwan Tangjitgamol

1

1 reference

21 August 2017

Benjamin O Anderson

2

1 reference

21 August 2017

Hui Ti See

3

1 reference

21 August 2017

Chawalit Lertbutsayanukul

4

1 reference

21 August 2017

Nakarin Sirisabya

5

1 reference

21 August 2017

Tarinee Manchana

6

1 reference

21 August 2017

Arunachalam Ilancheran

7

1 reference

21 August 2017

Khai Mun Lee

8

1 reference

21 August 2017

Siew Eng Lim

9

1 reference

21 August 2017

Yin-Nin Chia

10

1 reference

21 August 2017

Efren Domingo

11

1 reference

21 August 2017

Young-Tak Kim

12

1 reference

21 August 2017

Chyong-Huey Lai

13

1 reference

21 August 2017

Ahmad Zailani Hatta Mohd Dali

14

1 reference

21 August 2017

Wisit Supakapongkul

15

1 reference

21 August 2017

Sarikapan Wilailak

16

1 reference

21 August 2017

Eng-Hseon Tay

17

1 reference

21 August 2017

John Kavanagh

18

1 reference

21 August 2017

Asian Oncology Summit

19

1 reference

21 August 2017

publication date

1 November 2009

1 reference

Lancet Oncology Commission

21 August 2017

published in

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

11

1 reference

21 August 2017

page(s)

1119-1127

1 reference

Global cancer statistics, 2002

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Theories of endometrial carcinogenesis: a multidisciplinary approach

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer: implications for gynecologic surveillance.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

The role of transvaginal ultrasound or endometrial biopsy in the evaluation of the menopausal endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Gynecologic oncology group trials in uterine corpus malignancies: recent progress

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Laparoscopic-assisted vaginal versus abdominal surgery in patients with endometrial cancer--a prospective randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

The long-term survival of women with surgical stage II endometrioid type endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Assessment of depth of myometrial invasion in endometrial adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

The ability to evaluate prognostic variables on frozen section in hysterectomies performed for endometrial carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Radiation Therapy as Exclusive Treatment for Medically Inoperable Patients with Stage I and II Endometrioid Carcinoma of the Endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Medically inoperable stage I adenocarcinoma of the endometrium treated with radiotherapy alone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Exclusive radiation therapy in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

ACOG Practice Bulletin #65: Management of Endometrial Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Resection of lymph node metastases influences survival in stage IIIC endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Retrospective Analysis of Selective Lymphadenectomy in Apparent Early-Stage Endometrial Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Safety of ovarian preservation in premenopausal women with endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Ovarian preservation and staging in reproductive-age endometrial cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Assessment of prognostic factors in stage IIIA endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

When and how should adjuvant radiation be used in early endometrial cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Survival after relapse in patients with endometrial cancer: results from a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Clinical outcome with adjuvant treatment of endometrial carcinoma using intensity-modulated radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Clinical outcome of adjuvant treatment of endometrial cancer using aperture-based intensity-modulated radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

A randomized trial of adjuvant progestagen in early endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Progestagens for endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Chemotherapy in developing countries--is less better?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Present status and future direction of clinical trials in advanced endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Pelvic exenteration for recurrent endometrial cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Surgical treatment of recurrent endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Cytoreductive surgery for advanced and recurrent endometrial cancer: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Hormone replacement therapy after treatment of endometrial cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

ACOG committee opinion. Hormone replacement therapy in women treated for endometrial cancer. Number 234, May 2000 (replaces number 126, August 1993).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

Follow-up after primary therapy for endometrial cancer: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

The clinical value and the cost-effectiveness of follow-up in endometrial cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970290-6

7 January 2021

10.1016/S1470-2045(09)70290-6

Identifiers

DOI

1 reference

21 August 2017

1 reference